Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00633321 · ClinicalTrials.gov registry record · Phase 2
Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation
A Phase 2 study of Smoking, sponsored by Celtic Pharma Development Services.
- Completed
- Registry status
- Phase 2
- Development phase
- 522
- Enrollment target
- 9
- Study locations
NCT00633321 is a Phase 2 study of Smoking that has completed, run by Celtic Pharma Development Services. The registered enrollment target is 522 participants, above the 451-participant average among 123 other Smoking trials with a reported enrollment target (16% higher). The trial reports 9 study locations across 7 states.
The verdict
NCT00633321, a Phase 2 study of Smoking, has completed, sponsored by Celtic Pharma Development Services.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 522 participants
- Enrollment target
- 9
- Study locations
Study Summary
Over 1 billion people worldwide smoke, resulting in an estimated 4 million deaths annually from smoking-related disease.1 Persistent and long-term smoking leads to an increased risk of cardiovascular damage, respiratory disease, and a higher incidence of a variety of cancers; but for smokers who can quit there is an immediate and significant beneficial impact on their health and life expectancy. Cigarette smoking remains the leading preventable cause of death in the United States (US), accounting for approximately 1 of every 5 deaths (438,000 people) each year. This Phase 2 study will investigate the efficacy and tolerability of 2 doses of TA-NIC compared to placebo as an aid to smoking cessation in smokers who are motivated to quit.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL TA-NIC
Study Locations (9)
Maryland
- Columbia Medical Practice - Columbia
- Centennial Medical Group - Elkridge
Texas
- Benchmark Research - Austin
- Benchmark Research - Fort Worth - Fort Worth
California
- Benchmark Research - Sacramento
Louisiana
- Benchmark Research - Metairie
Minnesota
- Mayo Clinic - Rochester
New Jersey
- CNS Research Institute, P.C. - Clementon
Pennsylvania
- CRI Worldwide, LLC Kirkbride Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 522 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00633321
The ClinicalTrials.gov registry entry for NCT00633321 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 522 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 451-participant average among 123 other Smoking trials with a reported enrollment target (16% higher). The listed sponsor is Celtic Pharma Development Services, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoking appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00633321 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Maryland, Texas, California.
Frequently Asked Questions
What is clinical trial NCT00633321 about?
NCT00633321 is a clinical study titled "Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation". Over 1 billion people worldwide smoke, resulting in an estimated 4 million deaths annually from smoking-related disease.1 Persistent and long-term smoking leads to an increased risk of cardiovascular damage, respiratory disease, and a higher incidence of a variety of cancers; but for smokers who can...
What is the current status of trial NCT00633321?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 522 participants. The study started on 2007-05. Estimated completion is 2009-02.
What conditions does trial NCT00633321 study?
This clinical trial studies the following conditions: Smoking.
What interventions are being tested in trial NCT00633321?
The interventions under investigation include: Placebo (BIOLOGICAL), TA-NIC (BIOLOGICAL).
Who is sponsoring clinical trial NCT00633321?
This trial is sponsored by Celtic Pharma Development Services, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00633321 being conducted?
This trial has 9 study locations across California, Louisiana, Maryland, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Potential of Kava in Enabling Tobacco Cessation - Its Holistic Effects in Managing Stress and Insomnia Associated With Abstinence
RECRUITING · Phase 2
-
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
RECRUITING · Phase 2
-
App for Reducing Cravings to Smoke
RECRUITING · Phase 2
-
Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava
ACTIVE NOT RECRUITING · Phase 2
-
Proactive Health Intervention for Tobacco Users (Get PHIT)
COMPLETED · Phase 2
-
Computer-Assisted Intervention for Smoking During Pregnancy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.